deaths (OS)

mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population

versus ipilimumab alone
pembrolizumab (10mg/kg) vs. ipilimumab alone 1 certainty unassessablestatistically conclusive-29%
versus Standard of Care (SoC)
pembrolizumab (10mg/kg) vs. Standard of Care (SoC) 1 certainty unassessable-24%